BCLPX
Price
$8.67
Change
-$0.03 (-0.34%)
Updated
Jun 2 closing price
Net Assets
4.78B
EVDIX
Price
$22.73
Change
-$0.02 (-0.09%)
Updated
Jun 2 closing price
Net Assets
116.04M
Interact to see
Advertisement

BCLPX vs EVDIX

Header iconBCLPX vs EVDIX Comparison
Open Charts BCLPX vs EVDIXBanner chart's image
BCLPX vs EVDIX Comparison Chart in %
View a ticker or compare two or three
VS
BCLPX vs. EVDIX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCLPX is a Buy and EVDIX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
BCLPX has more cash in the bank: 4.78B vs. EVDIX (116M). BCLPX pays higher dividends than EVDIX: BCLPX (3.07) vs EVDIX (0.34). BCLPX was incepted earlier than EVDIX: BCLPX (18 years) vs EVDIX (16 years). BCLPX (2.36) is less costly to investors than EVDIX (1.84). BCLPX is a more actively managed with annual turnover of: 81.00 vs. EVDIX (76.80). BCLPX has a lower initial minimum investment than EVDIX: BCLPX (1000) vs EVDIX (1000000). EVDIX annual gain was more profitable for investors over the last year : 7.54 vs. BCLPX (3.88). EVDIX return over 5 years is better than : 8.83 vs. BCLPX (6.02).
BCLPXEVDIXBCLPX / EVDIX
Total Expense Ratio2.271.74130%
Annual Report Gross Expense Ratio2.361.84128%
Fund Existence18 years16 years-
Gain YTD1.2813.22140%
Front LoadN/AN/A-
Min. Initial Investment100010000000%
Min. Initial Investment IRAN/AN/A-
Net Assets4.78B116M4,121%
Annual Yield % from dividends3.070.34910%
Returns for 1 year3.887.5452%
Returns for 3 years14.8313.20112%
Returns for 5 years6.028.8368%
Returns for 10 years20.60111.6918%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MPB32.870.76
+2.37%
Mid Penn Bancorp
CPRX31.27N/A
N/A
Catalyst Pharmaceuticals
BCDA0.90-0.03
-2.71%
BioCardia Inc.
TEAM109.10-6.85
-5.91%
Atlassian Corp
GALT2.42-0.19
-7.28%
Galectin Therapeutics